IDYA Relative Valuation
IDYA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IDYA is overvalued; if below, it's undervalued.
Historical Valuation
IDEAYA Biosciences Inc (IDYA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 93.08 is considered Undervalued compared with the five-year average of -8.69. The fair price of IDEAYA Biosciences Inc (IDYA) is between 21.49 to 38.87 according to relative valuation methord. Compared to the current price of 21.16 USD , IDEAYA Biosciences Inc is Undervalued By 1.52%.
Relative Value
Fair Zone
21.49-38.87
Current Price：21.16
1.52%
Undervalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
1.81
P/B
Median3y
2.66
Median5y
2.55
-13.84
FCF Yield
Median3y
-8.78
Median5y
-5.51
Competitors Valuation Multiple
The average P/S ratio for IDYA's competitors is 48.90, providing a benchmark for relative valuation. IDEAYA Biosciences Inc Corp (IDYA) exhibits a P/S ratio of 93.08, which is 90.34% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is IDEAYA Biosciences Inc (IDYA) currently overvalued or undervalued?
What is IDEAYA Biosciences Inc (IDYA) fair value?
How does IDYA's valuation metrics compare to the industry average?
What is the current P/B ratio for IDEAYA Biosciences Inc (IDYA) as of Jul 08 2025?
What is the current FCF Yield for IDEAYA Biosciences Inc (IDYA) as of Jul 08 2025?
What is the current Forward P/E ratio for IDEAYA Biosciences Inc (IDYA) as of Jul 08 2025?